AI Article Synopsis
- Ischemic stroke (IS) leads to significant neurological damage and impacts many people globally, yet there is a lack of effective tools to predict patient outcomes.
- The review focuses on the IL-1 family of cytokines, detailing both pro-inflammatory molecules (like IL-1α and IL-1β) that could worsen tissue damage, and anti-inflammatory ones (like IL-1Ra and IL-37) that might protect the brain.
- Understanding the balance between these cytokines could offer insights into patient recovery and potential treatments, though further research is needed to fully grasp their roles in IS.
Article Abstract
Ischemic stroke (IS) is a critical medical condition that results in significant neurological deficits and tissue damage, affecting millions worldwide. Currently, there is a significant lack of reliable tools for assessing and predicting IS outcomes. The inflammatory response following IS may exacerbate tissue injury or provide neuroprotection. This review sought to summarize current knowledge on the IL-1 family's involvement in IS, which includes pro-inflammatory molecules, such as IL-1α, IL-1β, IL-18, and IL-36, as well as anti-inflammatory molecules, like IL-1Ra, IL-33, IL-36A, IL-37, and IL-38. The balance between these opposing inflammatory processes may serve as a biomarker for determining patient outcomes and recovery paths. Treatments targeting these cytokines or their receptors show promise, but more comprehensive research is essential to clarify their precise roles in IS development and progression.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11476913 | PMC |
| http://dx.doi.org/10.3390/ijms251910515 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!